Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial (DOXYPOSTOP)
Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- at least 18 years of age, of either sex and any race
- diagnosis of chronic rhinosinusitis with or without nasal polyposis according to the EPOS guidelines research
- Subjects should be regularly scheduled for bilateral functional endonasal endoscopic sinus surgery
- Subjects must be in good health, free of any clinically significant disease that would interfere with the study schedule or procedures or compromise his/her safety.
- Subjects must be willing to give informed consent and adhere to visit schedules, medication restrictions, and agree to perform daily diary entries.
- Nonpregnant women of childbearing potential must use a medically acceptable, adequate form of birth control.
Exclusion Criteria:
- Women must not be pregnant, breast feeding, or premenarcheal.
- Subjects who have required oral corticosteroids within the previous four weeks prior to surgery.
- Subjects who have required nasal corticosteroids within the previous one week prior to surgery.
- Subjects with known allergic reaction on tetracyclines, diabetes (type 1 and 2), renal insufficiency, severe liver disease, systemic diseases affecting the nose (e.g. M. Wegener), prior surgeries of the paranasal sinuses.
Patients with the following diseases should be excluded :
- Cystic fibrosis based on positive sweat test or DNA alleles
- Gross immunodeficiency (congenital or acquired)
- congenital mucociliary problems e.g. primary ciliary dyskinesia (PCD)
- Non-invasive fungal balls and invasive fungal disease
- systemic vasculitis and granulomatous diseases
- Cocaine abuse
- Neoplasia
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Placebo komparator: placebo
|
during 56 days
|
|
Eksperimentel: doxycycline 100 mg
|
during 56 days
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Endoscopic evaluation of quality and speed of wound healing
Tidsramme: at 3 months after first drug intake
|
at 3 months after first drug intake
|
|
Recurrence of nasal polyps
Tidsramme: at 3 months after first drug intake
|
at 3 months after first drug intake
|
|
Recurrence of nasal polyps
Tidsramme: at 6 months after first drug intake
|
at 6 months after first drug intake
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
nasal and exhaled NO
Tidsramme: at 3 months after first drug intake
|
at 3 months after first drug intake
|
|
nasal and exhaled NO
Tidsramme: at 6 months after first drug intake
|
at 6 months after first drug intake
|
|
subjective assessment of the wound healing
Tidsramme: at 3 months after first drug intake
|
at 3 months after first drug intake
|
|
subjective assessment of the wound healing
Tidsramme: at 6 months after first drug intake
|
at 6 months after first drug intake
|
|
chronic rhinosinusitis symptoms by the patients
Tidsramme: at 3 months after first drug intake
|
at 3 months after first drug intake
|
|
chronic rhinosinusitis symptoms by the patients
Tidsramme: at 6 months after first drug intake
|
at 6 months after first drug intake
|
|
Questionnaires: SNOT 22, RSOM, SF36 asthma control questionnaire
Tidsramme: at 3 months after first drug intake
|
at 3 months after first drug intake
|
|
Questionnaires: SNOT 22, RSOM, SF36 asthma control questionnaire
Tidsramme: at 6 months after first drug intake
|
at 6 months after first drug intake
|
|
inflammatory mediators in nasal fluid as well as in serum
Tidsramme: at 3 months after first drug intake
|
at 3 months after first drug intake
|
|
inflammatory mediators in nasal fluid as well as in serum
Tidsramme: at 6 months after first drug intake
|
at 6 months after first drug intake
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Claus Bachert, MD, PhD, University Hospital Ghent, Belgium
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Infektioner
- Luftvejsinfektioner
- Luftvejssygdomme
- Otorhinolaryngologiske sygdomme
- Patologiske Tilstande, Anatomiske
- Paranasale bihulesygdomme
- Næsesygdomme
- Polypper
- Bihulebetændelse
- Næsepolypper
- Anti-infektionsmidler
- Antibakterielle midler
- Antiprotozoale midler
- Antiparasitære midler
- Antimalariamidler
- Doxycyclin
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 2010/384
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .